Amneal Pharmaceuticals, Inc. Class A Stock News

–  Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization  Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“K...

–  Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost –

BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vial. Amneal plans to launc...

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Park...